Hikma Pharmaceuticals (HKMPY)

PNK: HKMPY · Real-Time Price · USD

52.97

0.00 (0.00%)

At close: Apr 30, 2025, 3:45 PM

Hikma Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q2 2024	Q4 2023	Q2 2023	Q4 2022	Q2 2022	Q4 2021	Q2 2021	Q4 2020	Q2 2020	Q4 2019	Q2 2019	Q4 2018	Q2 2018	Q4 2017	Q2 2017	Q4 2016	Q2 2016
Period Ending	Dec 31, 2024	Jun 30, 2024	Dec 31, 2023	Jun 30, 2023	Dec 31, 2022	Jun 30, 2022	Dec 31, 2021	Jun 30, 2021	Dec 31, 2020	Jun 30, 2020	Dec 31, 2019	Jun 30, 2019	Dec 31, 2018	Jun 30, 2018	Dec 31, 2017	Jun 30, 2017	Dec 31, 2016	Jun 30, 2016
Revenue	1.54B	1.57B	1.44B	1.43B	1.37B	1.21B	1.35B	1.22B	1.19B	1.13B	1.18B	1.04B	1.09B	979M	1.04B	895M	1.07B	882M
Cost of Revenue	932.52M	813M	813.48M	737M	745.81M	633M	718.63M	629M	620.68M	551M	584.76M	516M	555M	511M	553M	468M	567M	433M
Gross Profit	609.8M	756M	623.01M	690M	622.03M	580M	630.82M	587M	566.66M	581M	590.84M	527M	536M	468M	488M	427M	501M	449M
Operating Income	234.61M	351M	125M	348M	263.29M	255M	303.8M	296M	263.2M	290M	281.74M	253M	213M	215M	184M	152M	243M	158M
Interest Income	3.96M	4M	3.97M	3M	2.1M	1M	18M	1M	3.93M	5M	4.05M	3M	14M	24M	21M	28M	17M	29M
Pretax Income	165.32M	288M	78.37M	202M	18.88M	215M	226.08M	319M	278.91M	274M	268.56M	226M	152M	141M	-838M	100M	127M	83M
Net Income	131.66M	226M	58.53M	131M	15.73M	173M	174.61M	248M	215.08M	212M	305.05M	185M	176M	106M	-912M	69M	97M	58M
Selling & General & Admin	295.99M	280M	414.68M	260M	280.07M	256M	242.23M	232M	229.81M	229M	240.19M	216M	259M	208M	252M	222M	228M	201M
Research & Development	79.19M	61M	84.32M	64M	78.67M	69M	84.78M	59M	73.66M	62M	68.91M	58M	84M	63M	58M	63M	93M	57M
Other Expenses	n/a	64M	992.05K	-18M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Expenses	375.19M	405M	498.01M	342M	358.74M	325M	327.01M	291M	303.46M	291M	309.1M	274M	370M	303M	1.3B	299M	357M	337M
Interest Expense	43.56M	44M	42.66M	44M	46.15M	33M	31.29M	25M	29.46M	24M	27.36M	25M	n/a	n/a	n/a	n/a	n/a	n/a
Selling & Marketing Expenses	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	120M	116M	115M	106M
Cost & Expenses	-1.31B	1.22B	1.31B	1.08B	1.1B	958M	1.05B	920M	924.14M	842M	893.85M	790M	925M	814M	1.86B	767M	924M	770M
Income Tax Expense	33.66M	59M	17.86M	71M	1.05M	41M	53.49M	71M	64.82M	62M	-37.5M	41M	24M	32M	71M	30M	28M	24M
Shares Outstanding (Basic)	110.32M	111.88M	55.14M	55.25M	55.06M	56.75M	57.75M	57.75M	57.61M	60.5M	60.57M	60.54M	121M	121M	120M	120.5M	120M	114M
Shares Outstanding (Diluted)	111.52M	111.88M	55.8M	55.5M	55.06M	57M	58.61M	58M	58.31M	60.78M	60.73M	60.78M	121M	121M	120M	120.5M	120M	114M
EPS (Basic)	1.20	2.02	1.06	2.38	0.28	3.04	3.02	4.30	3.74	3.50	5.04	3.06	1.46	0.88	-7.6	0.58	0.80	0.50
EPS (Diluted)	1.18	2.02	1.04	2.36	0.28	3.04	2.98	4.28	3.68	3.48	5.02	3.04	1.46	0.88	-7.6	0.58	0.80	0.50
EBITDA	308.86M	427M	214.28M	446M	284M	341M	347.2M	422M	378.1M	362M	336.46M	310M	261M	266M	-721.47M	196M	295M	211M
EBIT	208.88M	331M	120.04M	309M	65.04M	248M	257.37M	344M	308.38M	298M	295.92M	251M	185.37M	215M	-789.91M	130M	169.14M	158M
Depreciation & Amortization	99.98M	96M	94.25M	96M	101.75M	93M	89.83M	78M	69.73M	64M	40.54M	59M	48M	51M	64M	61M	52M	53M